Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x100px

Organisation › Details

Forty51 Advisors AG

https://www.forty51ventures.com

Forty51 is a recently founded Venture Capital firm focused on early stage venture creation in Europe backed by a strong investor syndicate with Stable Asset Management, several Pension funds, family offices and accomplished Biotech entrepreneurs. *

	Start	2022-04-01 established
	Group	Forty51 Ventures (Group)
	Industry	venture capital
	Industry 2	BIOTECH
	Person	Núnez-Garcia, Sara (Forty51 Advisors 202204– Partner + Co-Founder formerly Sofinnova Partners 201410 Associate)
	Person 2	Bucher, Sascha-Oliver (Forty51 Advisors 202204– Partner + Co-Founder)

	Region	Basel BS
	Country	Switzerland
	Street	119 Engelgasse
	City	4052 Basel
		Address record changed: 2022-07-17

Basic data	Employees	n. a.

		* Document for »About Section«: Mosanna Therapeutics AG. (7/13/22). "Press Release: Mosanna Therapeutics Announces a Seed Financing Round to Advance Development of MOS-118 to Treat Metabolic Obstructive Sleep Apnea". Basel.

		Record changed: 2023-08-30

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

More documents for Forty51 Ventures (Group)

[1] Mysthera Therapeutics AG. (8/21/23). "Press Release: Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies". Basel....
[2] Forty51 Ventures. (7/18/22). "Press Release: Forty51 Ventures Announces the First Close of Fund I and its First Investment". Luxembourg & Basel....
[3] Mosanna Therapeutics AG. (7/13/22). "Press Release: Mosanna Therapeutics Announces a Seed Financing Round to Advance Development of MOS-118 to Treat Metabolic Obstructive Sleep Apnea". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]